Daniel E Bauer
Overview
Explore the profile of Daniel E Bauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
9197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lee J, Zeng J, Liu P, Nguyen M, Loustaunau D, Bauer D, et al.
bioRxiv
. 2024 Feb;
PMID: 38370706
Over the last 5 years, cytosine base editors (CBEs) have emerged as a promising therapeutic tool for specific editing of single nucleotide variants and disrupting specific genes associated with disease....
12.
13.
Casirati G, Cosentino A, Mucci A, Salah Mahmoud M, Ugarte Zabala I, Zeng J, et al.
Nature
. 2023 Aug;
621(7978):404-414.
PMID: 37648862
Despite the considerable efficacy observed when targeting a dispensable lineage antigen, such as CD19 in B cell acute lymphoblastic leukaemia, the broader applicability of adoptive immunotherapies is hampered by the...
14.
Dictys: dynamic gene regulatory network dissects developmental continuum with single-cell multiomics
Wang L, Trasanidis N, Wu T, Dong G, Hu M, Bauer D, et al.
Nat Methods
. 2023 Aug;
20(9):1368-1378.
PMID: 37537351
Gene regulatory networks (GRNs) are key determinants of cell function and identity and are dynamically rewired during development and disease. Despite decades of advancement, challenges remain in GRN inference, including...
15.
Marion W, Koppe T, Chen C, Wang D, Frenis K, Fierstein S, et al.
Leukemia
. 2023 Jun;
37(8):1698-1708.
PMID: 37391485
Many inherited bone marrow failure syndromes (IBMFSs) present a high risk of transformation to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). During transformation of IBMFSs, hematopoietic stem and progenitor...
16.
Klatt D, Brendel C, Bauer D
Mol Ther Methods Clin Dev
. 2023 Jun;
30:14-15.
PMID: 37332392
No abstract available.
17.
Zeng J, Nguyen M, Liu P, da Silva L, Lin L, Justus D, et al.
bioRxiv
. 2023 Jun;
PMID: 37292647
Gene editing the erythroid enhancer is a validated approach to fetal hemoglobin (HbF) induction for β-hemoglobinopathy therapy, though heterogeneity in edit allele distribution and HbF response may impact its safety...
18.
Essawi K, Hakami W, Khan M, Martin R, Zeng J, Chu R, et al.
Mol Ther Methods Clin Dev
. 2023 Jun;
29:483-493.
PMID: 37273902
CRISPR-Cas9-based therapeutic genome editing approaches hold promise to cure a variety of human diseases. Recent findings demonstrate pre-existing immunity for the commonly used Cas orthologs from (SpCas9) and (SaCas9) in...
19.
20.
Tesio N, Bauer D
Hematol Oncol Clin North Am
. 2023 Mar;
37(2):273-299.
PMID: 36907603
Thalassemia syndromes are common monogenic disorders and represent a significant health issue worldwide. In this review, the authors elaborate on fundamental genetic knowledge about thalassemias, including the structure and location...